Inactive Instrument

All News Biosyent Inc. Toronto S.E.

Equities

RX

CA0906901081

All News

BioSyent In-Licenses Endocrinology Product for Canada	06-12	GL
Ex-dividend day	05-30	FA
Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 13, 2023.	05-16	CI
BioSyent Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-16	CI
BioSyent Releases Financial Results for Q1 2024	05-16	GL
BioSyent Declares Second Quarter 2024 Dividend	05-16	GL
BioSyent Inc Declares Second Quarter 2024 Dividend, Payable June 15, 2024	05-16	CI
BioSyent Schedules Q1 2024 Earnings Release for May 16, 2024	05-09	GL
BioSyent to Attend Planet MicroCap Showcase	04-23	GL
BioSyent Inc.(TSXV:RX) dropped from S&P/TSX Venture Composite Index	04-21	CI
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement	04-15	GL
BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference	04-10	GL
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year	04-03	GL
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year	04-03	AQ
BioSyent To Present At LD Micro New York Investor Conference	04-01	MT
BioSyent to Present at LD Micro New York Investor Conference	04-01	GL
BioSyent Announces Grant of Restricted Share Units	03-27	GL
Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 13, 2022.	03-13	CI
Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 13, 2023.	03-13	CI
BioSyent Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Biosyent Inc. Toronto S.E.

Equities

RX

CA0906901081

All News

Filters